Paris, 13 July 2010 – NYSE Euronext today announced the admission to NYSE Alternext of CARMAT, a biomedical company pioneering the development of a fully implantable artificial heart.
The admission of CARMAT (ticker symbol: ALCAR) to NYSE Alternext was by the listing of 2,811,950 existing shares making up its capital, 161,107 new shares resulting from the conversion of convertible bonds (“OCA-2010”) and the exercise of equity warrants (“BSA-LI” and “BSA-OC”), and 827,002 new shares issued as part of a global offering, including the partial exercise of the Extension Option. The admission and issue price of CARMAT shares was set at EUR 18.75 each. The company’s market capitalization on the day of admission amounted to EUR 71.3 million.